Drug development

#Drug development #Drug discovery #Immuno-oncology #Infectious diseases #Neurodegenerative disorders

This week in drug discovery (26-29 July)

News round-up by DDW’s Megan Thomas for 26-19 July DDW’s Megan Thomas rounds up her top five stories this week which show how innovation in drug discovery is enhanced by collaboration, be it financial backing or through the combining of differing expertise to achieve a common goal. SARS-CoV-2 spike… Read More

#News #Trending News

#Alzheimer's #Drug development #Pharma #Research

New data supports targeting Trk receptors for treating Alzheimer’s

AlzeCure Pharma’s presentation and poster regarding the clinical candidate drug ACD856 for Alzheimer’s disease, presented at the Alzheimer’s Association International Conference (AAIC) 2021 on July 26-30 in Denver, USA, are now available on its website. The abstract, ACD856 – a novel positive allosteric modulator of Trk-signaling in clinical development for… Read More

#News

#Antimicrobials #Drug development #Drug discovery #Infectious diseases #R&D

£1.9 million to combat infectious disease and antimicrobial resistance

The Bloomsbury SET, a knowledge exchange programme led by The Royal Veterinary College (RVC), has been awarded £1.9 million from Research England. Beginning in July 2021, the year-long project aims to commercialise research into infectious disease and antimicrobial resistance. Building on the current work of The Bloomsbury SET, this new… Read More

#News

#Biosciences #Drug development #Drug discovery #Narrated podcasts

The benefits of robust colony management in drug discovery

In this podcast John Couse, Vice President of Scientific Services at Taconic Biosciences discusses the benefits of a robust colony management solution/partner in the drug discovery success; how it can enable companies to scale through resource management and create efficiencies. Couse has extensive knowledge of colony managements solutions and outlines… Read More

#Podcasts

#Biosciences #Drug development #Drug discovery #Podcast

The benefits of robust colony management in drug discovery – podcast

In this podcast John Couse, Vice President of Scientific Services at Taconic Biosciences discusses the benefits of a robust colony management solution/partner in the drug discovery success; how it can enable companies to scale through resource management and create efficiencies. Couse has extensive knowledge of colony managements solutions and outlines… Read More

#News

#Biochemistry #Drug development #Drug discovery #Life sciences #Microfluidics #Pharmaceuticals

Researchers develop tool to speed up the study of enzymes

Scientists understand that transformations that couldn’t historically be explained by conventional chemistry or physics alone are in fact powered by enzymes – protein molecules comprised of chains of amino acids that act to speed up, or catalyse, the conversion of one kind of molecule (substrates) into another (products). While more… Read More

#News

#Blood donation #Drug development #Research

BioIVT opens UK blood donor centre at London’s White City Campus  

BioIVT has moved its London blood donor centre to Imperial College London’s White City Campus, which is four times larger than its previous facility. BioIVT has seven global blood donor centres and supports the work of about 30,000 researchers worldwide. “We are responding to a rapidly… Read More

#News

#Covid-19 #Drug development #Drug discovery #Pharmaceuticals #RNA #SARS-CoV-2

SARS-CoV-2 spike protein induces lipid stripping from cell membrane

Scientists at the Institut Laue-Langevin (ILL), in collaboration with the Paul Scherrer Institut (PSI), the Institut de Biologie Structurale (IBS) and the Australian Nuclear Science and Technology Organisation (ANSTO), have published new data on how the SARS-CoV-2 spike protein interacts with mammalian lung cell membranes, allowing the viral… Read More

#Covid-19 #News #Trending News

#Biotherapeutics #Clinical trials #Drug development #Drug discovery #Pharma #Rare disease

This week in drug discovery (19 – 23 July)

News round-up by DDW’s Megan Thomas for 19 – 23 July DDW’s Megan Thomas rounds up her top five stories this week which facilitate the continuation of vital drug discovery research, from partnerships and funding to successful trials and informative reports. Exscientia accelerates Covid-19 drug discovery using AI Exscientia… Read More

#News #Trending News

#Drug development #Drug innovation #Funding #Research #Therapeutics

Orbit Discovery plans growth in peptide discovery business

Orbit Discovery has raised US$7.6 million which will be used to accelerate its growth as a provider of peptide discovery services to the biotechnology and pharmaceutical industry. Orbit Discovery’s novel bead-based and microfluidic technology platform enables the screening of peptide libraries for target binding and subsequent activity in cell-based functional… Read More

#News

#Biotherapeutics #Drug development #Parkinson's

Innovative CNS medicines partnership announced

Bial and Medis have partnered on two of Bial’s proprietary drugs: Zebinix (eslicarbazepine acetate) and Ongentys (opicapone). The established partnership comprises an exclusive distribution agreement for Zebinix in the Czech Republic and Slovakia and an exclusive distribution agreement for Ongentys in Bosnia and Herzegovina, Bulgaria, Croatia, the Czech Republic, Estonia,… Read More

#News

#AI #AI / data analytics / healthtech / informatics #Big pharma #Drug development #Drug discovery #GlobalData

AI and big data will continue to disrupt pharmaceutical sector, says research

The Covid-19 pandemic has given businesses opportunity to implement technology-fuelled changes to the way they operate. AI and big data/analytics have been identified by healthcare industry professionals as the top technologies that will transform pharmaceutical drug discovery and development processes, as well as marketing and sales, according to a survey… Read More

#Market Reports #News #Trending News #Trends & Analysis

#Bioscience #Biotechnology #Cell and gene therapy #Cell and Gene Therapy Catapult #Drug development #Life sciences #Research

GSK unveils plan for one of Europe’s largest life science campuses

GSK has announced that it planning to develop its research & development site in Stevenage, UK,  into one of Europe’s largest clusters for biotechnology and early-stage life science companies. The concept has been developed in partnership with Stevenage Bioscience Catalyst (SBC), among others and would build on GSK’s existing presence,… Read More

#News

#Biopharmaceuticals #Biotechnology #Drug development #Investment #Pharmaceuticals #Therapeutics

New laboratory boosts high-potency drug development

US-based Continuus Pharmaceuticals has opened a new laboratory space and new technology to help the development of high-potency drugs. The new lab and technology are the latest developments in Continuus’ ongoing expansion, coming six months after receiving a US$69.3 million US government contract for the domestic production of medicines. “Our… Read More

#News

#Biotherapeutics #Clinical trial #Clinical Trial Authorisation #Drug delivery #Drug development #Therapeutics

FDA Fast Track designation for Parkinson’s Disease treatment

BlueRock Therapeutics has been granted Fast Track designation by the US Food and Drug Administration (FDA) for DA01 for advanced Parkinson’s disease (PD). DA01, BlueRock’s pluripotent stem cell-derived dopaminergic neuron therapy, is under evaluation in a Phase I study. “Receiving Fast Track Designation from the FDA is an important step,… Read More

#News

#3D modelling #Clinical trials #Drug development #Drug discovery

Lonza and CN Bio hepatocyte distribution agreement

Lonza and CN Bio have entered into a distribution agreement where Lonza will supply a selection of hepatic cells to be prequalified by CN Bio for use in its PhysioMimix Single-and Multi-Organ MPS. The aim is to change the way human-relevant pre-clinical data is generated. With prequalified cells, customers can… Read More

#News